High­er dose of Spin­raza helped spinal mus­cu­lar at­ro­phy pa­tients, Bio­gen says

Bio­gen on Wednes­day said that an ex­per­i­men­tal, high­er dose of its spinal mus­cu­lar at­ro­phy drug Spin­raza met the pri­ma­ry end­point of a clin­i­cal tri­al com­par­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER